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Mechanisms of constitutive NF-kB signaling in multiple myeloma are unknown. An inhibitor of IkB
kinase b (IKKb) targeting the classical NF-kB pathway was lethal to many myeloma cell lines. Several
cell lines had elevated expression of NIK due to genomic alterations or protein stabilization, while
others had inactivating mutations of TRAF3; both kinds of abnormality triggered the classical and
alternative NF-kB pathways. A majority of primary myeloma patient samples and cell lines had ele-
vated NF-kB target gene expression, often associated with genetic or epigenetic alteration of NIK,
TRAF3, CYLD, BIRC2/BIRC3, CD40, NFKB1, or NFKB2. These data demonstrate that addiction to
the NF-kB pathway is frequent in myeloma and suggest that IKKb inhibitors hold promise for the
treatment of this disease.INTRODUCTION
Multiple myeloma (MM), a malignancy of plasma cells
(PCs), was diagnosed in over 16,000 people in the US in
2005 and contributed to over 11,000 deaths (Jemal et al.,
2006). The current standard treatment of MM includes
high-dose chemotherapy and stem cell transplantation.
New agents with broad or undefinedmolecular specificity,
such as the proteasome inhibitor bortezomib and the
thalidomide analog lenalidomide (Barlogie et al., 2004;
Mitsiades et al., 2004), can prolong survival but have asso-ciated toxicities. There is a clear need for new therapeutic
strategies targeting defined pathogenetic events in MM.
Previous studies suggested the importance of NF-kB
signaling in MM, by the nuclear presence of NF-kB in MM
cells and the sensitivity of someMM cell lines to NF-kB in-
hibition (Hideshima et al., 2002; Hideshima et al., 2006).
Within the bone marrow microenvironment, NF-kB signal-
ing in stromal cells can lead to production of IL6, BAFF, or
APRIL, knowngrowth factors for andactivators ofNF-kB in
MM (Hideshimaet al., 2002;Marsters et al., 2000;Moreaux
et al., 2005).SIGNIFICANCE
Here we show the importance of classical NF-kB signaling in multiple myeloma. We discovered diverse genetic
and epigenetic mechanisms leading to NF-kB activity in myeloma cell lines and patient samples. Targeted disrup-
tion of classical NF-kB signaling with a small-molecule inhibitor of IKKb blocked myeloma cell proliferation and
induced cell death. Most primary MM patient samples had evidence of NF-kB pathway activation, suggesting
that therapeutic strategies targeting the classical NF-kB pathway should be pursued.Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc. 115
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NF-kB in Multiple MyelomaFigure 1. NF-kB Activation and IKKb
Inhibition
(A) Schematic of NF-kB signaling.
(B) Growth inhibition of MM cell lines by the
IKKb inhibitor MLN120b (MLN). Cell lines
were cultured in the presence of MLN
(25 mM), and cells were enumerated by flow
cytometry as described (Davis et al., 2001).
After 12 days, cell numbers were determined
and displayed relative to a control culture
treated with the same volume of DMSO
(solvent) alone.Five subunits combine into hetero- and homodimers to
create the NF-kB transcription factor family (Ghosh and
Karin, 2002), yielding two general pathways of activation
(Figure 1A). In the classical pathway, IKKb phosphorylates
the inhibitory subunits IkBa, IkBb, or IkB3, leading to their
degradation in the proteasome. As a result, the NF-kBhet-
erodimers p50/p65 and c-rel/p65 accumulate in the nu-
cleus. In the alternative pathway, IKKa homodimers phos-
phorylate p100/NFKB2, resulting in proteasomal removal
of an inhibitory C-terminal domain and generating the
NF-kB p52 subunit (Senftleben et al., 2001; Xiao et al.,
2001). Consequently, the p52/RelB heterodimers prefer-
entially accumulate in the nucleus.
Various cancer types utilize constitutive NF-kB signal-
ing to block apoptosis (Basseres and Baldwin, 2006),
but themolecularmechanisms leading to constitutive IKKb
activation in cancer are largely unknown. Cancer-causing
mutations in the NF-kB pathway could lead to overactiva-
tion of positive inputs to NF-kB activation, or loss of neg-
ative regulators. The NF-kB-inducing kinase (NIK) falls into
the former category. NIK is necessary for alternative NF-
kB signaling initiated by various members of the TNF
receptor (TNFR) superfamily (Claudio et al., 2002; Coope
et al., 2002; Ramakrishnan et al., 2004; Yin et al., 2001).
However, NIK is required for signaling to the classical
pathway by certain TNF family members, such as CD40
ligand and BAFF (Ramakrishnan et al., 2004). When over-
expressed, NIK can activate the classical pathway, with
resultant IkB degradation and nuclear translocation of116 Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc.p50/p65 and/or c-rel/p65 (O’Mahony et al., 2000; Woro-
nicz et al., 1997).
Negative regulators act on many steps in the NF-kB
pathway. TRAF3, a putative ubiquitin ligase, can inhibit
signaling to both the classical and alternative NF-kB path-
ways by TNFR family members (Hauer et al., 2005) and
may exert this effect, in part, by mediating NIK protein
degradation (Liao et al., 2004; Xiao and Sun, 2000). The tu-
mor suppressor CYLD inhibits the NF-kB pathway at mul-
tiple steps by deubiquitinating the IKKg subunit, TRAF2,
TRAF6, and BCL3 (Brummelkamp et al., 2003; Kovalenko
et al., 2003; Massoumi et al., 2006; Regamey et al., 2003;
Trompouki et al., 2003). The ubiquitin ligase cIAP1 can at-
tenuate NF-kB signals via TNFR family members (Li et al.,
2002; Rothe et al., 1995a).
In the present study, we discovered diverse genetic ab-
normalities causing constitutive NF-kB signaling in MM.
Gene expression profiling revealed that the NF-kB path-
waywas activated inMMwith surprising frequency. These
genetic and functional data provide a molecular frame-
work for the rational development of NF-kB pathway
inhibitors for the therapy of multiple myeloma.
RESULTS
Sensitivity of Myeloma Cell Lines to IKKb Inhibition
We examined the toxicity of a small-molecule inhibitor of
IKKb, MLN120b (MLN) (Nagashima et al., 2006), in 21 cell
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NF-kB in Multiple MyelomaFigure 2. Effect of IKKb Inhibition on NF-kB Signaling in MM Cells
(A) Steady-state levels of NF-kB subunits in cytoplasmic or nuclear-enriched protein fractions from cell lines.
(B) Effect of IKKb inhibition by MLN on the abundance of NF-kB subunits and of total and phosphorylated IkBa.
(C) Effect of IKKb inhibition on the nuclear DNA-binding activity of the NF-kB p65 and p52 subunits. Binding to an oligonucleotide containing the
NF-kB consensus sequencewasmeasured in nuclear extracts prepared fromMMcells treatedwithMLN for the indicated times. DNA-binding activity
was quantified by colorimetry (mean ± SD).
(D) NF-kB target genes in MM. L363 cells were treated with the IKKb inhibitor MLN for the indicated times, and gene expression changes were
assessed using DNA microarrays and depicted according to the color scale shown.
(E) Affymetrix U133plus2.0 microarray data from 47 MM cell lines were ordered using the average of the 11 NF-kB target genes determined in (D),
median centered, and depicted according to the color scale shown.
(F) Abnormalities of NF-kB pathway components and regulators in the indicated cell lines.lines representing many different molecular subgroups of
MM. Twelve cell lines had moderate to high sensitivity,
three had intermediate sensitivity, and six were resistant
(Figure 1B). Cell lines showed varying degrees of apopto-
sis and growth arrest in response to IKKb inhibition (Fig-
ure S1 in the Supplemental Data available with this article
online).The presence of nuclear NF-kB subunits in cell lines
corresponded with their sensitivity to IKK inhibition. Nu-
clear p65 and p52 reflect activity of the classical and alter-
native NF-kB pathways, respectively. Both subunits were
detected in nuclear extracts from 12 MLN-sensitive cell
lines but were low or undetectable in nuclear extracts
from three resistant lines (Figure 2A).Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc. 117
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NF-kB in Multiple MyelomaThe level of IkBa phosphorylation decreased with IKKb
inhibition over time in two MLN-sensitive cell lines (Fig-
ure 2B). Nuclear p65 also decreased with MLN treatment,
but nuclear p52 remained unchanged. NF-kB motif DNA-
binding activity was measured in nuclear extracts from
five sensitive cell lines and one resistant cell line. DNA
binding by complexes containing p65 decreased after
IKKb inhibition, while p52 DNA binding was unaffected
(Figure 2C). This result is consistent with the specificity
of MLN for IKKb and the classical NF-kB pathway (Naga-
shima et al., 2006).
We defined an NF-kB target gene signature by profiling
gene expression changes with MLN treatment of L363
cells (Figure 2D). Eleven genes were consistently downre-
gulated by IKKb inhibition and correlated in expression
across 47 cell lines (Figure 2E). These same genes were
downregulated inMM cell line EJM upon retroviral expres-
sion of the IkBa super-repressor, a specific inhibitor of
classical NF-kB signaling (Davis et al., 2001), which was
toxic to both L363 and EJM cell lines (data not shown).
The expression levels of these NF-kB target genes were
combined to create an NF-kB signature average, which
was used to rank the cell lines. Notably, all MLN-sensitive
cell lines had higher NF-kB signature expression than the
MLN-insensitive cell lines (Figure 2E).
NF-kB Activity and Genetic Abnormalities
in Primary MM Cases
We analyzed the activity of the NF-kB pathway in gene ex-
pression profiles of 451 purified MM samples from newly
diagnosed patients (Shaughnessy et al., 2007; Zhan et al.,
2006). Each of the 11 NF-kB signature genes was signifi-
cantly correlated in expression with the others in the pri-
mary MM samples (r value range 0.63–0.87; Figure 3A).
Since these genes were identified solely based on activity
of the NF-kB pathway in myeloma cell lines, their coregu-
lation in primary patient samples suggests that they are
surrogates for NF-kB pathway activity. Indeed, the pro-
portion of MM cells with immunohistochemical evidence
of nuclear p65 correlated with the NF-kB signature in
patient samples (r = 0.71; p < 0.001) (Figure S2).
For each MM sample, the average of the 11 NF-kB sig-
nature geneswas calculated and used to rank the samples
(Figure 3A). Among the MM patient samples, 368 (82%)
had levels greater than that of MM-M1, the NF-kB-depen-
dent cell line with the lowest NF-kB signature expression.
These data suggest that amajority ofMMcases have func-
tionally significant levels of theNF-kB signature, compara-
ble to those in NF-kB-dependent cell lines.
We next compared the NF-kB signature levels in MM
with those in normal PCs and in monoclonal gammopathy
of undetermined significance (MGUS), a benign condition
that can progress to MM. Normal PCs had levels of the
NF-kB signature that were comparable, on average, to
those in MGUS and MM (Figure 3C). Among normal hu-
man B cell subpopulations, PCs had the highest expres-
sion of the NF-kB signature (Figure 3D), consistent with
their dependence on signals in the bone marrow microen-
vironment that trigger NF-kB (O’Connor et al., 2004). The118 Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc.high expression of the NF-kB signature inmanyMMcases
may therefore reflect a similar dependence on the micro-
environment. However, not all molecular subgroups of
MM had equivalent expression of the NF-kB signature:
the MF and LB subgroups had relatively high expression,
while a proliferative (PR) subgroup had low expression
(Figure 3E). Thus, the importance of the NF-kB pathway
may be contingent upon other molecular features of these
MM subgroups (Shaughnessy et al., 2007 Zhan et al.,
2006).
To search for oncogenic abnormalities that might confer
cell-autonomous NF-kB pathway activation in MM, we
evaluated the expression of known regulators of NF-kB
in patient samples. Genes with an ‘‘outlier’’ expression
profile are those with a dramatically high or low expression
in a subset of samples, which might reflect oncogenic
events such as translocations, amplifications, or genomic
deletions. Recently, a method to identify outlier genes was
described, which relies on a scaling transformation of the
expression data to accentuate extreme values (Tomlins
et al., 2005). A similar method identified MM cases with
FGFR3 and Cyclin D1 translocations (Zhan et al., 2002).
We modified this approach to account for gene expres-
sion differences between knownMMsubgroups, attempt-
ing to focus on outliers associated with NF-kBactivation in
several MM subgroups (see Experimental Procedures).
We chose a high cutoff for outlier gene expression to focus
on cases most likely to have genetic abnormalities affect-
ing mRNA expression levels.
Four candidate NF-kB regulators—NIK, CD40, TRAF3,
and CYLD—had outlier mRNA expression values in at
least five MM cases. For NIK and CD40, outlier cases
highly overexpressed the corresponding mRNA, whereas
for TRAF3 and CYLD, outlier cases had exceedingly low
mRNA levels (Figure 3F). In addition, six cases with high
NF-kB signature expression had exceedingly low expres-
sion of BIRC3 and the neighboring gene BIRC2, which
was notable since BIRC3 is in the NF-kB signature. Cases
with outlier levels of these NF-kB regulators were signifi-
cantly skewed toward high NF-kB signature expression
(Figure 3B). In many cases, the altered expression of
the outlier genes was due to genetic abnormalities (see
below).
Aberrations of the NIK Genomic Locus in MM
We first investigated the molecular basis for outlier ex-
pression of NIK, a kinase capable of activating both the
alternative and classical NF-kB pathways (Claudio et al.,
2002; Coope et al., 2002; O’Mahony et al., 2000; Ramak-
rishnan et al., 2004; Woronicz et al., 1997; Yin et al., 2001).
Five patient samples were clear outliers, with average ex-
pression that was 8.8-fold above the median (Figures 3B
and 3F; Figure S3). NIK outliers had high expression of
the NF-kB signature (Figures 3B and 3G).
By fluorescence in situ hybridization (FISH), three NIK
outlier cases had chromosomal translocations between
the NIK locus and the IGH locus (two cases) or the IGL
locus (one case) (Figure 4A). Since chromosomal translo-
cations or high-level amplifications lead to monoallelic
Cancer Cell
NF-kB in Multiple MyelomaFigure 3. Multiple Molecular Mechanisms Activate NF-kB in Bone Marrow PC from Untreated MM Patients
(A) Expression of NF-kB target genes in primary MM patient samples. Affymetrix U133plus2.0 gene expression profiling data from 451 purified bone
marrow plasma cell populations derived from untreated patients with MM (Zhan et al., 2006). Samples are ranked according to the average expres-
sion of the 11 NF-kB target genes. Expression was centered based on the median value in the MM cell lines (Figure 2E).
(B) MM samples with outlier gene expression and/or TRAF3mutations. Cases with highNIK orCD40 expression and cases with low TRAF3,CYLD, or
BIRC2/BIRC3 expression are indicated with colored markers. The remaining cases are indicated in black. The asterisks indicate cases with inactivat-
ing TRAF3 mutations.
(C) NF-kB signature expression in normal and malignant plasma cell types. Data are taken from Zhan et al. (2006, 2007).
(D) NF-kB signature expression at different stages of human B cell differentiation. Duplicate samples from each stage were profiled.
(E) Expression of the NF-kB signature in MM gene expression subgroups.
(F) Expression of the indicated genes in the cases with outlier expression versus other MM cases.
(G) Expression of the NF-kB signature in outliers. Shown is the NF-kB signature expression in outliers relative to the minimum expression in MM cell
lines sensitive to IKKb inhibition.
In (D)–(G), the mean value ± SE is depicted.mRNA expression, we developed RT-PCR assays to dis-
tinguish two common NIK alleles that differ by a single
nucleotide polymorphism (SNP). Three NIK outlier cases
had monoallelic NIK mRNA expression, one of which
was confirmed to have a translocation ofNIK by FISH (Fig-
ure 4A). Among four cases with intermediate (but not out-lier) NIK expression, NIKmRNA was expressed from both
alleles, consistent with transcriptional overexpression
(Figure 4A).
Two NF-kB-dependent cell lines (EJM, L363) had NIK
mRNA levels equivalent to those in the NIK outlier patient
samples (data not shown). In the EJM cell line, the NIKCancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc. 119
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NF-kB in Multiple MyelomaFigure 4. Amplification or Translocation of NIK in MM Cell Lines
(A) Chromosomal translocations of NIK in primary MM patient samples. Three samples with NIK translocated to either the IGH locus or the IGL locus
were documented by FISH (one representative sample shownat right). Other cases hadmonoallelic expression ofNIK, consistent with a chromosomal
translocation or other cis-acting event (see text for details). nd, not done.
(B) FISH analysis of NIK amplification in the EJM cell line. Two exposures are shown to illustrate the high-level NIK amplicon on 17q21.
(C) Southern blot of NIK amplification in the EJM cell line. Genomic DNAs from the indicated cell lines were digested with HindIII and hybridized with
a radiolabeled 568 bp PCR fragment amplified from NIK exon 15.
(D) FISH analysis of NIK translocation to the IGL locus in the L363 cell line. The signal from the 92 kb NIK PAC probe is split between the der(17) and
der(22) chromosomes and is also present on the wild-type chr 17. The der(17) contains NIK sequences juxtaposed to the IGL enhancer.
(E) Southern blot of theNIK translocation in the L363 cell line. HpaI digest of genomic DNA hybridizedwith aNIK probe (Chr17:40,769,557-40,770,000
[build35]) shows a 16.1 kb wild-type fragment in placental DNA and a 10.1 kb fragment in L363.
(F) Structure of the NIK translocation breakpoint in L363. CEN, centromeric end; TEL, telomeric end. The breakpoint on chr 17 is bp 40,778,164
(asterisk) and on chr 22 is bp 21,553,824 (asterisk) (NCBI build 35).
(G) Southern blot of the NIK translocation in JJN3 cells. HpaI digest of genomic DNA hybridized with NIK exon 5 probe shows the wild-type locus as
a 16.2 kb fragment. The translocated locus is a 9.0 kb fragment.
(H) Northern blot of NIKmRNA species. mRNA from L363 or JJN3 cells was hybridized with a radiolabeled cDNA probe derived from the 30 end of the
NIKmRNA. A wild-type 4.6 kb mRNA species was detected in L363 cells (17 hr exposure). JJN3 cells (5 day exposure) show the wild-type mRNA and
an additional 5.4 kb mRNA, presumably from the translocated allele.
(I) Schematic of the EFTUD2-NIK fusion protein in JJN3 (see text for details).locus was highly amplified, as judged by both FISH and
Southern blot (Figures 4B and 4C). In the L363 cell line,
FISH revealed a chromosomal translocation juxtaposing120 Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc.the NIK and the IGL locus (Figures 4D and 4E). The break-
point occurred 28 kb 50 of NIK, bringing the NIK promoter
in proximity to IGL enhancer elements (Figure 4F).
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NF-kB in Multiple MyelomaIn the JJN3 cell line, one NIK allele generated an aber-
rant restriction fragment that hybridized with a probe de-
rived from NIK exon 5 (Figure 4G). These cells expressed
a 5.4 kbNIKmRNA instead of the wild-type 4.6 kb species
(Figure 4H). Cloning of the aberrant NIK allele identified
a translocation fusing a 50 fragment of EFTUD2 to a 30 por-
tion of NIK, with the breakpoint between exons 11 and 12
of EFTUD2 and between exons 2 and 3 of NIK (Figure S4).
The translocation is predicted to generate a 5152 bp
mRNA encoding a 132 kD in-frame EFTUD2-NIK fusion
protein (Figures 4H and 4I), and these cells indeed ex-
pressed an aberrant, high-molecular-weight NIK protein
(Figure 6A). The EFTUD2-NIK fusion protein consists of
the N-terminal region of EFTUD2, containing a conserved
domain of unknown function, fused to the C-terminal NIK
kinase domain (Figure 4I).
Mutations, Deletions, and Silencing of TRAF3 in MM
By the outlier approach, 17 MM cases had low expression
of TRAF3, a negative regulator of NIK (Liao et al., 2004;
Xiao and Sun, 2000). On average, outliers expressed
TRAF3mRNA at levels 13-fold below the median (Figures
3B and 3F; Figure S3). TRAF3 outliers had high expression
of the NF-kB signature (Figures 3B and 3G).
In the NF-kB-dependent cell line OCI-My1, which does
not express TRAF3 mRNA, the TRAF3 gene could not be
amplified by PCR from genomic DNA (data not shown),
and array-based comparative genomic hybridization
(aCGH) analysis confirmed a homozygous TRAF3 deletion
(Figure 5A). We next constructed a quantitative PCR
(qPCR) assay for TRAF3 genomic copy number. Of the six
TRAF3 outliers analyzed, two had biallelic deletion, three
had monoallelic TRAF3 deletion (one of which had a
TRAF3 mutation on the remaining allele), and one had a
normal copy number (Figure 5B). In these cases, epige-
netic silencing or decreased mRNA stability due to non-
sense mediated decay may contribute to the low TRAF3
mRNA expression; indeed, case P993 had a frameshift
mutation of TRAF3 that resulted in early termination of
the protein (see below). Homozygous deletions of TRAF3
were not present in other ‘‘NF-kB-high’’ cases (NF-kB sig-
nature above the median; n = 12) or in NF-kB-low cases
(NF-kB signature in the lowest quintile; n = 12).
Next, we investigated whether somatic mutations might
inactivate TRAF3 in MM. We sequenced 11 exons of
TRAF3 in genomic DNA from ten cell lines and 47 samples
from newly diagnosed MM patients, including 6 TRAF3
outliers, 29 NF-kB-high cases, and 12 NF-kB-low cases.
Two cell lines and four patient samples had mutations re-
sulting in stop codons in exons 4, 9, 10, or 11 (Figure 5C).
All of these had high NF-kB signature expression (Figures
2F and 3B). The predicted TRAF3 protein in the LP1 cell
line would lack the C-terminal 283 amino acids, containing
the entire MATH domain crucial for interaction of TRAF3
with NIK and with members of the TNFR superfamily (Li
et al., 2003; Liao et al., 2004; Ni et al., 2000, 2004). Like-
wise, mutations in patient samples 727, 993 and 1645
would remove the entire MATH domain. In the ANBL6 cell
line, the C-terminal 144 amino acids would be lost due tothe mutation, producing a protein in which the MATH do-
main is disrupted. Themutation in patient sample 83would
similarly truncate the protein within the MATH domain. Of
note, all TRAF3 mutations were homozygous, suggesting
a strong selective pressure for these mutations in MM.
CYLD Deletion in NF-kB-Positive MM
Among genes that were silenced in outlier cases, the
NF-kB regulator most significantly associated with high
NF-kB signature expression was CYLD, a known negative
regulator of NF-kB signaling (Brummelkamp et al., 2003;
Kovalenko et al., 2003; Regamey et al., 2003; Trompouki
et al., 2003). Six MM cases had expression of CYLD
mRNA that was, on average, 37-fold below the median
(Figures 3B and 3F; Figure S3). CYLD outliers had high ex-
pression of the NF-kB signature (Figures 3B and 3G).
We quantifiedCYLD copy number by qPCR in five avail-
able samples fromCYLD outliers and found biallelic loss of
the locus in all (Figure 5E). Analysis of published aCGH
data from some of these cases (Carrasco et al., 2006) con-
firmed that the sixthCYLD outlier also had a biallelicCYLD
deletion (Figure 5D). In summary, homozygous CYLD de-
letions were present in all CYLD outliers and are thus a re-
current genetic event in multiple MM that is associated
with high NF-kB activity.
CD40 Overexpression in MM
CD40 signaling activates both the classical and alternative
NF-kB pathways (Berberich et al., 1994; Coope et al.,
2002; Qing et al., 2005; Ramakrishnan et al., 2004). Six
outlier cases expressed CD40 mRNA levels that were
34-fold above the median (Figures 3B and 3F; Figure S3).
CD40 outliers had high expression of the NF-kB signature
(Figures 3B and 3G). Of note, the NF-kB-dependent cell
line XG2 expressed CD40 mRNA at a 24-fold higher level
than the average in other cell lines, suggesting that it may
have originated from aCD40 outlier MMcase. Since CD40
is an NF-kB target gene in certain lymphoma types (Lam
et al., 2005), we investigated whether the high CD40 ex-
pression in the outliers could be due to their high NF-kB
signature expression. We chose 60 control cases with
an average NF-kB signature expression equivalent to that
of the outliers. In these controls, the average CD40 ex-
pression was 23-fold lower than that of the outliers (p =
5.2 3 109). Therefore, the high CD40 expression in the
outliers is not primarily due to their NF-kB activity.
qPCR of the CD40 locus in three of the outlier cases did
not reveal high-level amplification, nor did the XG2 cell line
have CD40 amplification by aCGH (data not shown). The
mechanism ofCD40 overexpression in these cases is cur-
rently unknown but could be due to chromosomal translo-
cation or trans-acting regulatory mechanisms.
Other Genetic Abnormalities Affecting
the NF-kB Pathway in MM
Several cell lines had high NF-kB signature expression but
lacked genetic alterations in NIK, TRAF3, CD40, or CYLD
(Figure 2F). We therefore examined these cell lines for
alterations in other components of the NF-kB pathway.Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc. 121
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NF-kB in Multiple MyelomaFigure 5. Genetic Abnormalities of the Negative NF-kB Regulators TRAF3 and CYLD in MM
(A) Genomic deletion of TRAF3 in the OCI-MY1 cell line. aCGH estimated copy number from the TRAF3 genomic region in OCI-MY1 versus a normal
reference. Blue line indicates average ratio for probes within wild-type regions. The area depicted is 3 Mb on chr 14 (NCBI build 35). Probes within
the region encompassed by TRAF3 (red) indicate genomic deletion of the TRAF3 gene.
(B) qPCR analysis of TRAF3 copy number. Copy number estimates of TRAF3 relative to a control locus in six primary MM cases. Also shown is
average copy number (±SE) in 12 cases, each with high or low NF-kB signature expression, and in ten normal control samples.
(C) Mutations in TRAF3 that truncate the protein. Base pairs are numbered based on the TRAF3 reference sequence NM_145725. Resequencing
revealed nucleotide deletions or mutations in two NF-kB-positive MM cell lines (LP-1, ANBL-6) and in four patient samples. These changes produced
early termination of the TRAF3 protein at the positions indicated in the diagram. Each mutation would delete all or part of the carboxy-terminal MATH
domain required for binding to NIK and TNF receptor superfamily members.
(D) Comparison of aCGH and gene expression data for CYLD in MM samples. Cases are ranked according to their aCGH signals (Agilent probe
420863) relative to wild-type, with negative values indicating deletion, and compared with CYLD gene expression levels. The fourCYLD gene expres-
sion outliers for which array CGH data were available are indicated.
(E) qPCR analysis ofCYLD copy number. Copy number estimates ofCYLD relative to a control locus in five primary MM cases. Also shown is average
copy number (±SE) in 12 cases, each with high or low NF-kB signature expression, and in ten normal control samples.OCI-My5 and KMM1 had high expression of NFKB1, with
mRNA levels that were 4.5-fold and 18-fold higher expres-
sion than the median, respectively. aCGH revealed an
25-fold amplification of the NFKB1 gene in OCI-My5
(Figure S5A).
Two other cell lines, CAG and JK6L, had genetic abnor-
malities inNFKB2, encoding the p100 and p52NF-kB sub-
units.Western blot revealed truncated forms of theNFKB2
protein (Figure S5B). JK6L had a homozygous frameshift
mutation in NFKB2, disrupting the C-terminal ankyrin re-122 Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc.peat domains, whereas CAG had a genomic deletion in-
volving the NFKB2 30 exons that truncated the mRNA
and protein (Figures S5B–S5E). Such alterations were
previously described in MM and other hematological
malignancies and lead to nuclear forms of NFKB2 protein
that are presumably constitutively active (Migliazza et al.,
1994).
Examination of NF-kB target gene expression revealed
that KMS18 and KMS28PE had exceedingly low expres-
sion of BIRC3, encoding the ubiquitin ligase cIAP2. These
Cancer Cell
NF-kB in Multiple Myelomatwo cell lines also had low expression of BIRC2, a gene
that is next to BIRC3 in the genome and encodes cIAP1, a
ubiquitin ligase that inhibits TNFR signaling (Li et al., 2002).
qPCR revealed that KMS18 and KMS28PE have homozy-
gous deletions of the BIRC2/BIRC3 chromosomal locus
(Figure S5F). Six MM patient samples with low outlier ex-
pression of BIRC3 and BIRC2 (see above), and biallelic
deletions in the BIRC2/BIRC3 locus were detected by
aCGH and/or qPCR (Figures S5F and S5G). All cell lines
and patient samples with BIRC2/BIRC3 deletions had
NF-kB signature expression above the median (Figures
2F and 3B), suggesting that inactivation cIAP1 and/or
cIAP2 may modulate the NF-kB pathway in MM.
NIK Protein Expression in MM Cell Lines
To explore the molecular mechanisms by which NIK over-
expression activates the NF-kB pathway in MM, we first
investigated the expression of NIK protein in cell lines. A
high level of NIK protein was detected in five cell lines that
were sensitive to IKKb inhibition, including three with NIK
genomic aberrations (EJM, JJN3, L363) but also two with
no evidence of NIK aberrations (KMS28PE, KMS18) (Fig-
ure 6A). JJN3 cells had a 132 kD NIK protein instead of
the 104 kD wild-type protein, which presumably is the
EFTUD2-NIK fusion protein. A low level of NIK protein
was detected in four other NF-kB-dependent cell lines
(ANBL6, OCI-MY1, XG2, U266). Other NF-kB-dependent
cell lines (OCI-My5, LP1, KMS28BM) lacked detectable
NIK protein, as did all three NF-kB-negative cell lines
(H929, JIM3, UTMC2).
The cell lines KMS18, KMS28PE, and JJN3 expressed
NIK mRNA at an average level (Figure 6B), suggesting
that these cell lines have translational or posttranslational
mechanisms to elevate NIK protein levels. To investigate
the latter possibility, we blocked protein synthesis with
cycloheximide and monitored NIK protein abundance
over time. The NIK protein in L363 cells was labile, with
a half-life of less than 5 min, but the NIK proteins in
KMS18, KMS28PE, and JJN3 were more stable, with half-
lives greater than 30 min (Figure 6C). Treatment of L363
cells with the proteasome inhibitor bortezomib increased
NIK protein levels dramatically, consistent with rapid
protein turnover by ubiquitin-mediated proteolysis (Fig-
ure 6D). Proteosomal inhibition in KMS18 cells increased
NIK protein levels to a much more modest extent (Fig-
ure 6D).
These data suggest that the high NIK protein levels in
KMS18, KMS28PE, and JJN3 cells are achieved by post-
translational stabilization of NIK protein. In JJN3, the
EFTUD2-NIK fusion protein lacks amino acids 78–84
of NIK, required for TRAF3-mediated degradation of
NIK, which could account for the stability of this protein.
In KMS18 and KMS28PE, no alterations in the TRAF3-
binding domain were present (data not shown).
Intriguingly, both of these lines lack expression of BIRC2
and BIRC3 due to genomic deletions (Figure S5C), raising
the possibility that cIAP1 and/or cIAP2 may play a role in
NIK protein stability.NIK Overexpression Activates NF-kB Signaling
and Blocks Cell Death in MM
To examine the functional significance of NIK overexpres-
sion inmyeloma cell lines, we designed short hairpin RNAs
(shRNAs) targeting NIK and expressed them in cell lines in
an inducible fashion using retroviruses (Ngo et al., 2006).
Two shRNAs against NIK were identified, one targeting
the coding region and the other the 30 untranslated region
(UTR),whichwere capable of knocking down thewild-type
NIKmRNA and protein expression (Figures 7A and 7B) as
well as the EFTUD-NIK fusion protein in JJN3 (Figure 7F).
Induction of NIK shRNAs proved toxic to four cell lines
with high NIK protein expression but not to four cell lines
with low or absent NIK expression (Figure 7C). To demon-
strate that NIK shRNA toxicity was due to knockdown of
NIK protein, we performed a complementation experi-
ment. EJM cells were engineered to express an exoge-
nous NIK mRNA containing the coding region but lacking
the 30UTR. Expression of the 30UTR-directed NIK shRNA
in these cells was predicted to knock down the endoge-
nous NIK mRNA but spare the exogenous NIK mRNA.
Whereas the NIK shRNA was toxic for control EJM cells,
cells expressing the exogenous NIK mRNA were rescued
from this toxicity (Figure 7D). This experiment demon-
strates that the NIK shRNA does not have appreciable
off-target toxicity and supports the conclusion that NIK
Figure 6. NIK Protein Overexpression in MM Cell Lines
(A) Western blot of NIK protein levels in cytoplasmic extracts from the
indicated cell lines. The wild-type NIK protein is a 104 kD protein
whereas the EFTUD2-NIK fusion protein in JJN3 is 132 kD.
(B) Relative NIKmRNA levels in cell lines as assessed by gene expres-
sion profiling on Affymetrix U133plus2.0 arrays (probe ID 205192_at).
(C) Enhanced NIK protein stability in a subset of myelomas. Western
blot of NIK and tubulin levels before and after protein synthesis
inhibition with cycloheximide.
(D) Proteasomal degradation of NIK varies in MM cell lines. L363 or
KMS18 cells were treated with cycloheximide (20 mg/ml) or the protea-
some inhibitor bortezomib (250 nM) for the indicated times and as-
sayed for NIK levels.Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc. 123
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(A) Quantitative RT-PCR measurement of NIK mRNA levels following induction of the NIK shRNA in EJM cells.
(B) Western blot of NIK protein levels following induction of the NIK shRNA in EJM cells.
(C) Knockdown of NIK is toxic to NIK-overexpressing MM cell lines. The indicated cell lines were transduced with a retrovirus expressing the NIK
shRNA (see Experimental Procedures). Live cells were enumerated by FACS and normalized to the value at day 2 following retroviral infection.
(D) Expression of the NIK coding sequence rescues cell lines transduced with an shRNA targeting the NIK 30UTR. EJM cells expressing a NIK coding
region cDNAor control EJMcells were transducedwith a retrovirus expressing an shRNA targeting theNIK 30UTR. Live cellswere enumerated as in (C).
(E) Knockdown of NIK inhibits nuclear NF-kB DNA binding. DNA-binding activity by the indicated NF-kB subunits was quantified by ELISA.
(F) Knockdown of the EFTUD2-NIK fusion protein in JJN3 cells affects NF-kB signaling via classical and alternative pathways.
(G) Inhibition of IKK activity by knockdown of NIK in MM cell lines. EJM cells expressing an IkBa-luciferase fusion protein were superinfected with the
indicated shRNAs. Induction of shRNAs targeting NIK caused a rise in luciferase activity indicating inhibition of IKK activity. Negative control shRNA
targets DsRed; positive control shRNA targets luciferase.
(H) Inhibition of NF-kB target gene expression following knockdown of NIK in EJM cells. Relative expression of the NF-kB signature in shRNA induced
versus uninduced cells is depicted.
(I) Western blot analysis of IKKa expression after induction of shRNAs targeting IKKa or luciferase. EJM cells were transduced with retroviral vectors
expressing the indicated shRNAs, and expression of IKKa and tubulin was monitored at the indicated times.124 Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc.
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cell lines.
We next investigated whether knockdown of NIK af-
fected constitutive NF-kB signaling in MMcells. WhenNIK
shRNA expression was induced, nuclear extracts had re-
duced DNA-binding activity of p50, p65, p52, and RelB,
suggesting that NIK knockdown affected both the classi-
cal and alternative NF-kB pathways (Figure 7E). Likewise,
knockdown of the EFTUD2-NIK fusion protein in JJN3 de-
creased phosphorylation of IkBa and abundance of nu-
clear p52, suggesting that this NIK protein also activates
the classical and alternative pathways (Figure 7F).
The effect of NIK knockdown on IkBa kinase activity
was measured in EJM cells engineered to express an
IkBa-Photinus luciferase fusion protein, which increases
in abundance when IKK activity is inhibited (Lam et al.,
2005; Ngo et al., 2006). Induction of NIK shRNA increased
luciferase activity, whereas an shRNA targeting DsRed
had no effect and an shRNA targeting Photinus luciferase
decreased the luciferase signal (Figure 7G). These data
were consistent with the NF-kB DNA-binding assays and
suggest that NIK functions upstream of IKKb in this cell
line. Accordingly, NF-kB target gene expression de-
creased in EJM cells during NIK knockdown (Figure 7H).
Since NIK can activate the alternative NF-kB pathway
via IKKa, we tested whether IKKa depletion was toxic to
the NIK-expressing cell line EJM. Two IKKa shRNAs
strongly inhibited the expression of IKKa protein (Fig-
ure 7I). In contrast to theNIK shRNAs, these IKKa shRNAs
were not toxic to EJM cells (Figure 7J) or other NIK-ex-
pressing cells (L363, JJN3, KMS28PE; data not shown),
suggesting that the toxicity of NIK shRNAs was not due
to blockade of the alternative NF-kB pathway.
TRAF3 Inactivation Promotes NF-kB Signaling
and Cell Survival in MM
To investigate the influence of TRAF3 loss on NF-kB sig-
naling in MM, we engineered two TRAF3-deficient cell
lines, OCI-My1 and LP1, to express TRAF3 in a doxycy-
cline-inducible fashion (Figure 8A). In both cell lines,
TRAF3 induction was followed by a decrease in IkBa
phosphorylation together with a decrease in total IkBa
levels (Figure 8A). TRAF3 induction also led to a decrease
in NF-kB signature expression (Figure 8B) and an increase
in the IkBa-luciferase reporter (Figure 8C), indicative of
IKK inhibition. DNA-binding activities of p50, p65, p52,
and RelB in the nuclei of OCI-My1 cells were all decreased
by TRAF3 induction (Figure 8D), suggesting that TRAF3
negatively regulates both the classical and alternative NF-
kB pathways in these cells. Finally, induction of TRAF3
was toxic to both OCI-My1 and LP1, but not to H929,
KMS28PE, and KMS28BM, which do not have TRAF3 ab-
normalities (Figure 8E). Together, these data suggest that
TRAF3 inactivation in MM is likely to promote cell survival
via NF-kB pathway activation.DISCUSSION
The present study defined diverse molecular mechanisms
activating NF-kB inMM.Most primary MM cases had high
expression of the NF-kB signature. This observation sug-
gests frequent engagement of the NF-kB pathway in my-
eloma for several reasons. First, the NF-kB signature
genes were defined based on IKKb inhibition and coex-
pression in myeloma cell lines, yet were nevertheless
highly correlated in expression across primary patient
samples. Second, the presence of the NF-kB p65 subunit
in the nucleus of primary MM cells correlated with NF-kB
signature expression. Finally, the genetic and epigenetic
alterations that we defined were significantly skewed to-
ward high NF-kB signature expression, in bothMMpatient
samples (p = 1.013 109) and cell lines (p = 1.083 1017)
(Figures 2F, 3B, 3C, and 3G).
Some NF-kB pathway activation is likely related to sig-
nals that PCs receive in the bone marrow microenviron-
ment. Indeed, among B cell subsets, normal PCs ex-
pressed the highest level of the NF-kB signature,
presumably due to BAFF- and APRIL-mediated signaling
(Hideshima et al., 2002; Marsters et al., 2000; Moreaux
et al., 2005; O’Connor et al., 2004). Blockade of BAFF
and APRIL decreases the number of bone marrow PCs
in normal mice (O’Connor et al., 2004), raising the possibil-
ity that similar pharmacological inhibition might prove
toxic to those MM cells that retain a microenvironmental
dependence for NF-kB pathway activation.
However, themost compelling evidence for a critical role
of the NF-kB pathway in myeloma pathogenesis was pro-
vided by the multiple, recurrent genetic abnormalities that
we uncovered in the pathway. In cell lines and primary
patient samples, NIK overexpression arose due to ampli-
fication or translocation of the NIK locus or due to en-
hanced NIK protein stability. An additional NF-kB-activat-
ing mechanism involved loss of functional TRAF3, either
by homozygous deletion, inactivating mutations, or epige-
netic silencing. Other genetic events associated with high
NF-kB activity in MM included CYLD or BIRC2/BIRC3
deletion, CD40 overexpression, NFKB1 amplification,
and NFKB2 C-terminal truncation. Most of these genetic
events increased classical and alternative NF-kB activity
in MM cell lines, leading to pathway addiction and sensi-
tivity to IKKb inhibition. Taken together, these myriad ge-
netic abnormalities strongly support the development of
IKKb inhibitors for the treatment of multiple myeloma.
NIK overexpression in MM cell lines activated both the
classical and alternative NF-kB pathways. In normal
mouse hematopoietic cells, loss of NIK does not affect
activation of the classical pathway by inflammatory stimuli
(Yin et al., 2001). However, NIK is required for the activa-
tion of the classical NF-kB pathway by certain TNF re-
ceptor family members, including CD40 (Ramakrishnan
et al., 2004). Further, experimental overexpression of
NIK can activate IKKb and the classical pathway via(J) Knockdownof IKKa is not toxic to aNIK-overexpressingmyeloma. EJMcellswere transducedwith shRNAs targeting IKKa,NIK, orDsRed. Live cells
were enumerated as in (C).Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc. 125
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(A) Inducible expression of TRAF3 in LP-1 and OCI-My1 cells decreases phosphorylated-IkBa (pIkB).
(B) Inhibition of NF-kB target gene expression following expression of TRAF3 in LP-1 cells. Relative expression of the NF-kB signature in TRAF3
induced versus uninduced cells is depicted.
(C) Inhibition of IKK activity by expression of TRAF3. OCI-My1 cells expressing an IkBa-luciferase fusion protein were superinfected with retroviruses
expressing either wild-type TRAF3 or an EGFP-TRAF3 fusion protein. Induction of TRAF3 caused a rise in luciferase activity indicating inhibition of IKK
activity.
(D) Effect of TRAF3 expression in OCI-My1 cells on the nuclear DNA-binding activity of the NF-kB p50, p65, p52, and RelB subunits. Binding to an
oligonucleotide containing the NF-kB consensus sequence was measured in nuclear extracts prepared from cell lines induced to express TRAF3
relative to uninduced cells for the indicated times. DNA-binding activity was quantified by colorimetry (mean ± SD).
(E) Toxicity of TRAF3 expression in LP-1 and OCI-My1 cell lines with TRAF3 inactivation. The indicated myeloma cell lines were transducedwith a ret-
rovirus expressing TRAF3. Live cells were enumerated by FACS and normalized to the value at day 2 following retroviral infection.phosphorylation of IKKb in its activation loop (Delhase
et al., 1999; O’Mahony et al., 2000). Indeed, NIK can
form a complex with IKKa and IKKb (Woronicz et al.,
1997), perhaps by virtue of its ability to directly bind
IKKa (Regnier et al., 1997). Studies conflict on the exact126 Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc.mechanism of IKKb activation by NIK (Delhase et al.,
1999; O’Mahony et al., 2000) but concur that NIK overex-
pression can activate IKKb, supporting our finding that
high NIK levels activate the classical NF-kB pathway in
some myelomas.
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promotes tumor cell survival in MM is by stimulating
IKKb and activating the classical NF-kB pathway for sev-
eral reasons. First, the toxicity of MLN for NIK-expressing
MM cells argues for an essential role of IKKb signaling:
MLN is highly selective for IKKb, with more than 1000-
fold greater inhibitory activity for IKKb than for 30 other
cellular kinases, including IKKa (Nagashima et al., 2006).
The IkBa super-repressor, which also specifically turns
off the classical NF-kB pathway, resulted in similar toxicity
and gene expression changes in these MM cells. Second,
NIK depletion by shRNA inhibited IkBa kinase activity.
Since IKKb is a far more potent IkBa kinase than IKKa,
this result suggests that NIK is activating IKKb in these
cells. Third, NIK knockdown decreased nuclear DNA-
binding activity of the classical NF-kB subunits p50 and
p65, consistent with an effect on IKKb activity. Fourth,
two shRNAs that effectively decreased IKKa protein ex-
pression were not toxic for NIK-expressing cell lines.
These data support the argument that NIK acts through
IKKb to stimulate the classical NF-kB pathway, thereby
promoting MM survival. Nonetheless, the alternative NF-
kB pathway was also affected by NIK knockdown since
p52 and RelB DNA-binding activity was reduced. It is
therefore conceivable that activity of the alternative NF-
kB pathway could contribute to the effect of NIK on cell
survival.
Multiple mechanisms lead to high NIK protein expres-
sion in MM. The wild-type NIK protein had a very rapid
turnover, and proteasome inhibition caused accumulation
of NIK protein, consistent with a ubiquitin-mediated deg-
radative pathway involving TRAF3, as described (Liao
et al., 2004). Nevertheless, whenwild-typeNIKmRNAwas
expressed at extraordinarily high levels due to chromo-
somal aberrations, as in L363 and EJM cells, wild-type
NIK protein accumulated. Cells with intermediate NIK
mRNA levels engage various mechanisms to stabilize
NIK protein. In JJN3 cells, a chromosomal translocation
precisely removed the region of NIK that TRAF3 requires
to destabilize NIK protein (Liao et al., 2004), highlighting
the interrelationship of TRAF3 and NIK in MM pathogene-
sis. KMS28PE and KMS18 had enhanced stability of NIK
protein without evident alterations in the TRAF3-binding
domain of NIK or in TRAF3 itself. Both KMS18 and
KMS28PE had genomic deletions of theBIRC2/BIRC3 ge-
nomic locus, which encodes the ubiquitin ligases cIAP1
and cIAP2. cIAP1 attenuates NF-kB signaling from
TNFR2 (Li et al., 2002), raising the possibility that this pro-
tein or cIAP2 may also inhibit NF-kB signaling down-
stream of NIK by decreasing NIK protein stability.
Another recurrent mechanism of NF-kB activation in
myeloma was silencing, homozygous deletion, or somatic
mutation of TRAF3. In primary MM patient samples, 4.4%
had a TRAF3 abnormality, and these cases had higher NF-
kB signature expression than other myelomas. Homozy-
gous TRAF3 deletions occurred in two primary cases
and in the OCI-My1 cell line. In addition, two NF-kB-de-
pendent cell lines and four primary patient samples car-
ried homozygous mutations creating truncated TRAF3Cproteins that should be incapable of interacting with NIK
or TNFR superfamily members. In cases lacking deletion
or mutation of TRAF3, low TRAF3 mRNA expression may
be due to epigenetic silencing, a frequent event in cancer.
Experimental re-expression of TRAF3 in cell lines lack-
ing functional TRAF3 decreased IKKb activity and both
classical and alternative NF-kB signaling, resulting in cell
death. TheprecisemechanismbywhichTRAF3modulates
IKK activity in these cell lines remains to be elucidated. The
cell lines with inactive TRAF3 do not have high NIK protein
expression.Moreover, oneof the TRAF3mutant cells, LP1,
was not affected by the NIK shRNA. In this cell line, there-
fore, TRAF3 must affect IKKb activity by a NIK-indepen-
dent mechanism.
In primary MM, the full consequence of TRAF3 inactiva-
tion may only be evident in cells dependent on NF-kB sig-
naling from a TNFR family member that can be negatively
regulated by TRAF3 (Hauer et al., 2005). The most logical
candidate cytokines to propagate TRAF3-deficient MM
are BAFF and APRIL, which are abundant in the bonemar-
row and can signal through TACI and BCMA, two TNFRs
that are highly expressed in a subset of MM (Moreaux
et al., 2005).
It is also notable that extreme overexpression of CD40,
a TNFR family member, was associated with NF-kB acti-
vation in MM. CD40 and other members of the TNFR su-
perfamily can activate NF-kB when overexpressed, even
in the absence of ligand (Lee et al., 1996; Rothe et al.,
1995b; Yamamoto et al., 1998). It is therefore plausible that
the 34-fold average overexpression of CD40 in the CD40
outlier cases is sufficient to activate NF-kB in a cell-auton-
omous fashion.
A key negative regulator of NF-kB signaling is CYLD,
which was homozygously deleted in primary MM cases
with highNF-kBsignature expression. CYLD is a deubiqui-
tinating enzyme that removes ubiquitin moieties from ac-
tivated TRAF2, TRAF6, IKKg, and BCL3, thereby interfer-
ing with NF-kB signaling at multiple regulatory levels
(Brummelkamp et al., 2003; Kovalenko et al., 2003; Mas-
soumi et al., 2006; Regamey et al., 2003; Trompouki
et al., 2003). Of note, CYLD was ineffective in inhibiting
NF-kB activity induced by NIK overexpression (Kovalenko
et al., 2003).
It therefore appears that diverse upstream signaling
pathways activate IKKb in MM. Further, some myelomas
may bypass the requirement for IKK altogether by ampli-
fying and overexpressing NFKB1, encoding the p50 sub-
unit of the classical NF-kB pathway, or by creating trun-
cated and constitutively active NFKB2 proteins. The
recurrent yet varied nature of these genetic abnormalities
suggests strongly that activity of the NF-kB pathway is the
phenotype that is selected rather than any particular
genetic lesion.
Overall, we documented genetic abnormalities in the
NF-kB pathway in 13 (28%) MM cell lines and 41 (9%) of
the primary MM samples. Considering that we rese-
quenced TRAF3 in only 10% of the patient samples,
a larger number of TRAF3mutations probably exist within
our sample set. Therefore, the total number of geneticancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc. 127
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be 16%. Given the large number and variety of genetic
abnormalities discovered in the present report, there
may well be genetic aberrations in other components of
the NF-kB pathway that we have not studied. As already
mentioned, however, many MM cases with high NF-kB
signature expression may not have genetic abnormalities
in the NF-kB pathway but rather may derive activating sig-
nals from the microenvironment. Irrespective of whether
the activation of the NF-kB pathway is cell intrinsic or
cell extrinsic, the MM cell may nonetheless depend
upon this pathway for survival.
A clear message from these recurrent yet varied genetic
abnormalities is that the NF-kB pathway plays a pervasive
role in the pathogenesis of MM, providing a strong impe-
tus to the development of NF-kB pathway inhibitors for
the therapy of this malignancy. Currently, IKKb inhibitors
are under development for clinical use and are likely to
have manageable on-target side effects (Nagashima
et al., 2006). That the majority of MM cell lines tested re-
tained a dependence on NF-kB signaling for survival is en-
couraging and consistent with previous results (Hide-
shima et al., 2006). The NF-kB signature provides
a basis to develop biomarkers of response to NF-kB path-
way inhibitors. A gauge of NF-kB activity, such as quanti-
tative RT-PCR to measure the 11-gene NF-kB signature,
could be assessed in bonemarrowMM samples both pre-
treatment and during administration of the drug. Coupling
biomarkers with pathway-targeted therapeutics will ulti-
mately allow treatment of MM patients to be tailored to
the genetic abnormalities of their cancers.
EXPERIMENTAL PROCEDURES
Primary MM Patient Samples
Primary MM cells were purified from bone marrow aspirates obtained
under approval of the Institutional Review Board of the University of
Arkansas for Medical Sciences (Little Rock, AR). Written informed con-
sent was documented. MM plasma cells were isolated by CD138
immunomagnetic bead selection (Zhan et al., 2006).
Cell Culture, Retroviral Constructs, and Transduction
MMcell lines were maintained in RPMI 1640 or ACL-4medium supple-
mented with 10% fetal calf serum (Hyclone) and penicillin/streptomy-
cin (Invitrogen) with or without 10 ng/ml IL-6 (R&D Systems). The IKKb
inhibitor MLN120b was provided by Millennium Pharmaceuticals
(Cambridge, MA). For efficient retroviral transductions, cell lines were
engineered to express the murine ecotropic retroviral receptor (Lam
et al., 2005). Certain cell lines were also engineered to express the bac-
terial tetracycline repressor (TETR) (Ngo et al., 2006). All inducible con-
structs in TETR lines were activated by doxycycline (20 ng/ml).
To assess toxicity of an shRNA, retroviruses that coexpressed GFP
were used as described (Ngo et al., 2006). In brief, flow cytometry was
performed 2 days after retroviral infection to determine the initial GFP-
positive proportion of live cells for each shRNA, then cells were subse-
quently cultured with doxycycline to induce shRNA and sampled over
time. The GFP-positive proportion at each time was normalized to that
for the control shRNA (against luciferase), and further normalized to the
initial value.
The cell-based assay for IKK activity was performed as described
(Ngo et al., 2006) using a TETR cell line engineered to express Renilla
luciferase and a fusion protein of IkBa and firefly luciferase (IkBa-Pho-
tinus); after infection with shRNA vectors and puromycin selection,128 Cancer Cell 12, 115–130, August 2007 ª2007 Elsevier Inc.shRNAwas induced and samples weremeasured for the two reporters
using the Dual-Glo luciferase assay system (Promega).
FISH
Three-color FISH assays of metaphase chromosomes derived from
MM cell lines were performed as described (Shou et al., 2000). In ad-
dition to the previously described immunoglobulin probes, a 92 kb
PAC (AC003963, version gi:2978476) was used as a probe forNIK. Us-
ing the same probes, NIK copy number alterations and NIK-IGH and
NIK-IGL gene fusions were evaluated by triple color interphase FISH
on mononuclear cells from bone marrow aspirates of newly diagnosed
disease (Hanamura et al., 2006).
Polymorphism to Distinguish NIK Alleles
A CT polymorphism at base pair 3020 (reference mRNA NM_003954)
in the 30 untranslated region ofNIK RNAwas identified from the human
EST database. Sequence analysis of PCR products from genomic
DNA was determined for 16 MM cell lines and 14 primary MM tumors.
Nine samples each had only C or T alleles, and 12 samples had both C
and T. When both alleles were present, the assay was repeated using
cDNA to distinguish mono- versus biallelic expression.
Cloning of Translocation Breakpoints
Southern blotting was used to identify rearranged HpaI genomic frag-
ments within or near theNIK gene for the L363 and JJN3 cell lines. Ge-
nomic libraries were made from HpaI fragments modified with BamHI
adaptors that were cloned in the lDash II vector (Stratagene) and then
screenedwith the probes used for the Southern blots. The sequence of
inserts was obtained directly (L363) or from a PCR product (JJN3).
Western Blot and ELISA
Protein was harvested fromMM cell lines and fractionated using a Nu-
clear/cytosol fractionation kit (BioVision). Protein was quantified using
the BCA method (Pierce) and separated by SDS-PAGE on a 4%–12%
acrylamide gradient. Nuclear protein was analyzed for NF-kB activity
using the TransAm NF-kB family kit (Active Motif). The following
antibodies were used: NIK, phospho-IkBa (Cell signaling), IkBa, p65
(SantaCruz Biotechnologies), p52/p100 (Upstate), B-tubulin (Sigma),
histone H2B (Imgenex).
qPCR
Copy number of TRAF3, BIRC2, BIRC3, and CYLD was measured in
DNA extracted from CD138+ MM samples or mononuclear cells puri-
fied from peripheral blood of normal donors. qPCRwas performed and
normalized to the PRKCQ locus as described (Rosenwald et al., 2003).
Primer sequences are listed in the Supplemental Experimental Proce-
dures.
aCGH
DNA fromMMcell lines was labeled fluorescently with Cy5, and normal
control genomic DNA was labeled with Cy3. These probes were cohy-
bridized to 400,000 element Nimblegen whole-genome arrays. Inten-
sity of hybridized probes was determined using an Axon scanner,
and data were analyzed with Nimblegen Scanarray software. Previous
aCGH data on 47 MM samples were downloaded for comparison with
gene expression (Carrasco et al., 2006).
Gene Expression Profiling and Analysis
Lymphochip DNA microarrays were utilized as described (Alizadeh
et al., 2000). Normal human B cell subsets were purified as described
(Alizadeh et al., 2000; Nilsson et al., 2000) and profiled following linear
mRNA amplification (see Supplemental Experimental Procedures for
details). Microarray data from primary MM samples were obtained
from http://www.ncbi.nlm.nih.gov/geo/ (accession number GSE2658)
(Shaughnessy et al., 2007; Zhan et al., 2006).
Genes comprising the NF-kB signature in MM were those that were
decreased in expression by >40% in at least six of eight time points fol-
lowing treatment of L363 cells with MLN for 8–24 hr in three separate
Cancer Cell
NF-kB in Multiple Myelomaexperiments (accession number GSE8487). Genes were chosen if
they correlated in expression across the MM cell lines (r > 0.5). See
the Supplemental Data for Affymetrix U133plus2.0 probe sets used
for analysis.
Analysis of outlier gene expression was performed as described
(Tomlins et al., 2005). Briefly, data from each Affymetrix probe set
were median centered across all samples. The absolute difference
from the median was calculated for each sample, and the data were
scaled such that the median of these values was 1 (log2). Outlier
gene expression was defined to be any scaled values greater than 5
(log2). In other words, compared to the median deviation of samples
from the median, outlier cases had >32-fold larger deviation. For
a set of cases with outlier expression of a particular gene, the associ-
ation of this outlier profile with the NF-kB signature was calculated by
comparing expression of the NF-kB signature in outliers versus other
cases using a Student’s t test. To adjust for the influence of gene
expression differences among known MM subgroups (Zhan et al.,
2006), we fitted an analysis of variance model for log signal of the
NF-kB signature, including MM subgroup as a categorical variable
and outlier status as a two-categorical variable.
The p value describes the association of NF-kB pathway abnormal-
ities with high NF-kB signature expression, based on a Wilcoxon
signed rank test.
See the Supplemental Data for additional Experimental Procedures.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, five supplemental figures, and array CGH data from OCI-My1
and OCI-My5 cell lines and can be found with this article online at
http://www.cancercell.org/cgi/content/full/12/2/115/DC1/.
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